Join us for a conversation between Mr. John Rim, President and CEO of Samsung Biologics, and Tom Byrne, the President and CEO of The Korea Society. In this second episode of the ‘President’s Interview Series,’ President Rim will discuss his extensive career and senior leadership roles in the biopharmaceutical industry, as well as his current role as the head of Samsung Biologics. With over 30 years of experience, President Rim played a key leadership role in facilitating the growth of Samsung Biologics into one of the world’s largest contract development and manufacturing organization (CDMO).
This interview will also provide an opportunity to learn more about the role of Samsung Biologics in the global biopharmaceutical industry including the recent agreement with the US biotech firm, Moderna, for fill-finish manufacturing of its path breaking mRNA COVID-19 Vaccine. This program was recorded at Samsung Biologics headquarters in Songdo, Incheon when President Byrne recently visited South Korea.
Talking COVID-19 Vaccine Cooperation
with
John Rim
Samsung Biologics
President & CEO
Premieres: Wednesday, July 21, 2021 | 7 PM (EDT)
The Korea Society
350 Madison Avenue, 24th Floor
New York, NY 10017
ABOUT THE SPEAKER:
John Rim
President & CEO
Samsung Biologics
John Rim is the President and Chief Executive Officer of Samsung Biologics, a global leading contract development and manufacturing organization (CDMO). Prior to being appointed CEO in December 2020, John served as Executive Vice President at Samsung Biologics and was a key senior leader in driving the company’s success with his global business acumen and a strong focus on client satisfaction.
Rim was also instrumental in rapidly expanding business growth across Samsung Biologics and for the continuous operational excellence in Plant 3, which holds the world’s largest biomanufacturing capacity at a single site. With over 30 years of experience in the biopharmaceutical industry, John has built a diverse and successful career, holding a number of senior global leadership roles across a range of markets and disciplines.
Prior to joining Samsung Biologics in 2018, Rim worked for Roche/Genentech in Technical Operations, Product Development, and Research & Development in the US and Europe. He has also held senior leadership roles with Astellas Pharmaceuticals in General Management, Sales & Marketing, Technical Operations, Customer Service, Business Development, and Strategic Planning. Rim began his career as a management consultant with Booz, Allen & Hamilton consulting to pharmaceutical companies in the US and Europe.
John received his bachelor’s degree from Columbia University, a master’s degree from Stanford University, and an MBA from the Kellogg School of Management at Northwestern University.
